EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Verve Therapeutics's Enterprise Value is $-31.66 Mil.
Verve Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-158.83 Mil. Therefore, Verve Therapeutics's EV-to-FCF for today is 0.20.
The historical rank and industry rank for Verve Therapeutics's EV-to-FCF or its related term are showing as below:
VERV'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.66 Med: -3.8 Max: 0.37
Current: 0.29
During the past 5 years, the highest EV-to-FCF of Verve Therapeutics was 0.37. The lowest was -14.66. And the median was -3.80.
VERV's EV-to-FCF is ranked better than 82.7% of 393
companies
in the Biotechnology industry
Industry Median: 4.52
vs VERV: 0.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Verve Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Verve Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Verve Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verve Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verve Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Verve Therapeutics's EV-to-FCF falls into.
Verve Therapeutics's current Enterprise Value is $-31.66 Mil.
Verve Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-158.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Verve Therapeutics's PE Ratio for today is calculated as:
Verve Therapeutics's share price for today is $6.355.
Verve Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Verve Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Verve Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Verve Therapeutics (Verve Therapeutics) Business Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VERV has been successfully added to your 